EBV Entry and Spread in the Oral Cavity
EBV 进入口腔并传播
基本信息
- 批准号:7871395
- 负责人:
- 金额:$ 35.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-01-15 至 2014-05-31
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAddressAdultAgeAppearanceB-Cell DevelopmentB-LymphocytesBehaviorBenignBindingBiological AssayCell fusionCell membraneCellsChildhoodComplement 3d ReceptorsComplement ReceptorComplexDataDiseaseDysplasiaEpithelialEpithelial CellsEpitheliumEquilibriumEventFailureGoalsHIVHerpesviridaeHumanHuman Herpesvirus 4Immune systemIncidenceIndividualIndolentInfectionInfectious MononucleosisInflammationIntegrin BindingIntegrinsLaboratoriesLeadLengthLifeLymphoidMalignant NeoplasmsMediatingMemory B-LymphocyteModelingMovementOncogenicOralOral cavityOropharyngealPathogenesisPlasmablastPlayPopulationPremalignant ChangePreneoplastic ChangeProcessProteinsPublishingRGD (sequence)ResearchRiskRisk FactorsRoleSatellite VirusesSeroepidemiologic StudiesStimulusSurface Plasmon ResonanceTestingTissuesTonsilTropismViral ProteinsViral load measurementVirusVirus DiseasesVirus ReplicationWorkWound Healingbaseenv Gene Productsimmunosuppressedin vivonew therapeutic targetpublic health relevancetraffickingtumortumorigenesisvirus envelope
项目摘要
DESCRIPTION (provided by applicant): Epstein-Barr virus (EBV) is an orally-transmitted human herpesvirus that establishes persistent infections in almost all adults worldwide. The reservoir of virus is in a latent state in the memory B cell population but current models suggest that it is replenished by sporadic reactivation in terminally differentiating plasmablasts, amplification in epithelial cells and reinfection of the B cell pool. Long term carriage of EBV can be associated with both lymphoid and epithelial malignancies and individuals who are immunosuppressed, particularly those infected with the human immunodeficiency virus (HIV), are at increased risk of developing them. Part of this increased risk may reflect a loss of control of replication of virus. The role that EBV plays in tumorigenesis is complex, but seroepidemiologic studies suggest that the disturbance of the normal equilibrium and an increase in virus load precedes the appearance of malignancy. The long term goal of this research is to understand the dynamics of infection, particularly how virus traffics between B cells and epithelial cells to amplify within the host. Five EBV envelope proteins have been differentially implicated in virus entry into B cells and epithelial cells, gp350, gH, gL, gp42 and BMRF2. New work from this laboratory suggests that preneoplastic changes in epithelial cells may make them more susceptible to infection as they differentially express cell proteins important for interaction with gHgL and gp350 and activate those that can induce virus replication in adjacent B cells. Further, that a newly identified envelope protein, BDLF2, which interacts with and may be dependent on BMRF2 may be relevant to virus spread. The immediate goals of this application are to test these hypotheses. Aim one will use soluble forms of gHgL and ?v?6, cell-based fusion assays and Surface Plasmon Resonance to evaluate interactions between gHgL and ?v?6 in triggering virus-cell fusion. The possibility that additional integrins can mediate the same function will be explored, the downstream effects of gH binding to integrins on intracellular movement of virus will be examined and the expression of integrins on normal and dysplastic tissues in vivo will be determined. Aim two will explore the role that CR2 plays in increasing efficiency of epithelial cell infection. Expression of CR2 on dysplastic epithelial cells in vivo will be evaluated and the effects on infection of a gp350-stimulated interaction with formins will be determined by comparison of full length and truncated CR2. Aim three will investigate the role of the BMRF2/BDLF2 complex by making a BDLF2-null virus and a BMRF2-null virus. A virus lacking the BMRF2 RGD motif will also be made to explore unique effects of gH and BMRF2 binding to integrins. EBV is one of a several viruses associated with oral complications of HIV disease reflecting its continued replication and shedding in the oropharynx. Unraveling mechanisms by which virus is targeted to cells newly prone to infection is important to understanding pathogenesis and developing evasive strategies PUBLIC HEALTH RELEVANCE: Epstein-Barr virus (EBV) is associated with several different malignancies and individuals with the human immunodeficiency virus are at increased risk of developing them. Part of this increased risk may represent a failure of the immune system to control EBV replication in epithelial cells. This application seeks to understand the interactions between virus and cell proteins that enable virus to enter epithelial cells and initiate replication and in doing so seeks to identify risk factors and potential novel therapeutic targets.
描述(由申请人提供):EB 病毒 (EBV) 是一种经口传播的人类疱疹病毒,在全世界几乎所有成年人中造成持续感染。病毒库在记忆 B 细胞群中处于潜伏状态,但目前的模型表明,病毒库通过终末分化浆母细胞中的零星重新激活、上皮细胞中的扩增和 B 细胞池的重新感染来补充。长期携带 EB 病毒可能与淋巴和上皮恶性肿瘤有关,而免疫抑制的个体,特别是感染人类免疫缺陷病毒 (HIV) 的个体,患上这些恶性肿瘤的风险增加。这种风险增加的部分原因可能是病毒复制失去控制。 EBV 在肿瘤发生中发挥的作用很复杂,但血清流行病学研究表明,正常平衡的破坏和病毒载量的增加先于恶性肿瘤的出现。这项研究的长期目标是了解感染的动态,特别是病毒如何在 B 细胞和上皮细胞之间流动并在宿主内扩增。五种 EBV 包膜蛋白 gp350、gH、gL、gp42 和 BMRF2 与病毒进入 B 细胞和上皮细胞有不同的相关性。该实验室的新工作表明,上皮细胞的肿瘤前变化可能使它们更容易受到感染,因为它们差异表达对于与 gHgL 和 gp350 相互作用至关重要的细胞蛋白,并激活那些可以诱导相邻 B 细胞中病毒复制的蛋白。此外,新发现的包膜蛋白 BDLF2 与 BMRF2 相互作用并可能依赖于 BMRF2,这可能与病毒传播有关。该应用程序的直接目标是测试这些假设。目标之一将使用可溶形式的 gHgL 和 ?v?6、基于细胞的融合测定和表面等离子共振来评估 gHgL 和 ?v?6 在触发病毒-细胞融合中的相互作用。将探索额外的整合素可以介导相同功能的可能性,将检查gH与整合素结合对病毒细胞内运动的下游影响,并确定整合素在体内正常和发育异常组织中的表达。目标二将探讨 CR2 在提高上皮细胞感染效率中的作用。将评估体内发育不良上皮细胞上CR2的表达,并通过比较全长和截短的CR2来确定gp350刺激的与福尔明相互作用对感染的影响。目标三将通过制作 BDLF2 无效病毒和 BMRF2 无效病毒来研究 BMRF2/BDLF2 复合物的作用。还将制造一种缺乏 BMRF2 RGD 基序的病毒,以探索 gH 和 BMRF2 与整合素结合的独特效应。 EBV 是与 HIV 疾病口腔并发症相关的几种病毒之一,反映了它在口咽中的持续复制和脱落。阐明病毒针对新易感染细胞的机制对于了解发病机制和制定规避策略非常重要。 公共卫生相关性:EB 病毒 (EBV) 与多种不同的恶性肿瘤相关,携带人类免疫缺陷病毒的个体患这些恶性肿瘤的风险增加。这种风险增加的部分原因可能是免疫系统无法控制上皮细胞中的 EBV 复制。该应用旨在了解病毒和细胞蛋白之间的相互作用,使病毒能够进入上皮细胞并启动复制,并在此过程中寻求识别风险因素和潜在的新治疗靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lindsey M. Hutt-Fletcher其他文献
Lindsey M. Hutt-Fletcher的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lindsey M. Hutt-Fletcher', 18)}}的其他基金
Anitbody and saliva-mediated enhancement of epithelial cell infection by EBV
抗体和唾液介导的 EBV 上皮细胞感染增强
- 批准号:
8103016 - 财政年份:2007
- 资助金额:
$ 35.17万 - 项目类别:
Anitbody and saliva-mediated enhancement of epithelial cell infection by EBV
抗体和唾液介导的 EBV 上皮细胞感染增强
- 批准号:
7487007 - 财政年份:2007
- 资助金额:
$ 35.17万 - 项目类别:
Anitbody and saliva-mediated enhancement of epithelial cell infection by EBV
抗体和唾液介导的 EBV 上皮细胞感染增强
- 批准号:
7886763 - 财政年份:2007
- 资助金额:
$ 35.17万 - 项目类别:
Anitbody and saliva-mediated enhancement of epithelial cell infection by EBV
抗体和唾液介导的 EBV 上皮细胞感染增强
- 批准号:
7655263 - 财政年份:2007
- 资助金额:
$ 35.17万 - 项目类别:
Anitbody and saliva-mediated enhancement of epithelial cell infection by EBV
抗体和唾液介导的 EBV 上皮细胞感染增强
- 批准号:
7450235 - 财政年份:2007
- 资助金额:
$ 35.17万 - 项目类别:
Epstein-Barr virus glycoproteins and virus spread
EB 病毒糖蛋白和病毒传播
- 批准号:
7557821 - 财政年份:2005
- 资助金额:
$ 35.17万 - 项目类别:
Epstein-Barr virus glycoproteins and virus spread
EB 病毒糖蛋白和病毒传播
- 批准号:
6984796 - 财政年份:2005
- 资助金额:
$ 35.17万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 35.17万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 35.17万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 35.17万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 35.17万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 35.17万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 35.17万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 35.17万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 35.17万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 35.17万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 35.17万 - 项目类别:
Research Grant